Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Capital Markets

China Isotope & Radiation Co / Equity Capital Markets

<p>China Isotope &amp; Radiation, the leading radiopharmaceuticals players in China, is raising up to USD 284 million in its listing in Hong Kong. In this insight, we will cover the following topics:</p><ul><li>The company's business segments and respective market positions</li><li>The company's growth driver and expansion plan</li><li>The Mo-99 supply chain that could affect the business</li><li>Our thoughts on valuation </li></ul>

China Isotope &amp; Radiation, the leading radiopharmaceuticals players in China, is raising up to USD 284 million in its listing in Hong Kong. In this insight, we will cover the following topics:The company's business segments and respective market positionsThe company's growth driver and expansion planThe Mo-99 supply chain that could affect the businessOur thoughts on valuation 

China Isotope & Radiation IPO: Oligopoly, Visible Growth and High Barrier to Entry